Rogaine Sales Climb 30% as GLP-1 Users Seek Hair Loss Relief

Rogaine sales are up 30 percent this year, and Kimberly-Clark's CEO thinks GLP-1 weight-loss medications may be part of the reason.

Mike Hsu flagged the growth on an analyst call, suggesting that rising use of GLP-1 drugs could be supporting demand for the topical hair loss treatment. Rogaine joined Kimberly-Clark's portfolio through its acquisition of Kenvue, and the brand has now delivered one of the more striking growth numbers in the consumer health category this year.

Here's the mechanism the market is watching. Rapid weight loss has been associated with temporary hair shedding — a phenomenon clinicians typically describe as telogen effluvium-style loss triggered by physiological stress, though the source stops short of naming it. That shedding creates additional demand for targeted hair care treatments, and minoxidil, Rogaine's active ingredient, is the most established over-the-counter option on the shelf.

One caveat matters for anyone drawing conclusions: a direct link between GLP-1 medications and Rogaine's sales growth has not been established. The 30 percent figure is real; the causal chain is not. Hsu himself framed the GLP-1 connection as a suggestion, not a finding.

How big is the prize?

The numbers frame why a 30 percent jump gets attention. Rogaine holds approximately 9 percent of the global hair loss prevention market, a segment valued at around US$10 billion in 2025 and projected to reach US$23 billion by 2035, according to Future Market Insights.

Do the arithmetic and the stakes become concrete. A 9 percent share of a US$10 billion market puts Rogaine's baseline business in the neighborhood of US$900 million a year. If the market's growth curve holds — more than doubling over the next decade — the segment adds roughly US$13 billion in annual value by 2035. A brand growing 30 percent in a single year is outpacing that trajectory by a wide margin.

To put the 30 percent in household terms: for every three bottles of Rogaine a pharmacy moved last year, it's moving four this year.

What does this change for dermatology practices?

The practical question for clinicians is patient volume. As GLP-1 adoption widens, more patients are likely to present with shedding complaints tied to rapid weight loss, and many will arrive already self-treating with OTC minoxidil. That shifts the consultation toward confirming the diagnosis, setting expectations that this shedding is typically temporary, and advising on proper minoxidil use — which dermatologists know is often inconsistent among unsupervised users.

The commercial signal is equally clear. Rogaine's performance shows growing demand for targeted hair loss treatments as changing consumer health and lifestyle trends reshape the global hair care market. An established brand is capturing new demand without a single new product launch — no reformulation, no new indication, just an existing minoxidil franchise meeting an emerging consumer need.

That's the part manufacturers across the category will study. If GLP-1-driven shedding persists as a demand driver, expect more positioning of hair loss products toward the weight-loss patient journey — and expect clinicians to field more questions about what's driving the hair in the drain.

For now, the data supports correlation, not causation. But with Rogaine growing 30 percent in a US$10 billion market headed for US$23 billion, the GLP-1 hair loss conversation has moved from anecdote to analyst call.